Go to deals
Consumer & Retail | Healthcare

Apostrophe has been acquired by Hims & Hers Health, Inc.

The private shareholders of Apostrophe have sold the company to Hims & Hers Health, Inc.

Founded in 2012 and based in Oakland, California, Apostrophe is a direct-to-patient teledermatology platform that provides individuals with access to tailored, clinical-quality treatment plans that are prescribed by board-certified dermatologists. Through its vertically integrated in-house pharmacy, the company creates premium Apostrophe-branded products that use bespoke combinations of topical formulas and oral medications to meet the unique needs of patients. Driven by its innovative telehealth model, well-recognized skincare brand and visionary leadership team, the company has experienced rapid growth over the past several years.

Based in San Francisco, California, Hims & Hers is a leading multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers.

Oaklins’ team in Los Angeles acted as advisor to the private shareholders of Apostrophe in this transaction.

Parties

Talk to the deal team

Adam Abramowitz

Managing Director
Los Angeles, United States
Oaklins Intrepid

Hayden Rosenthal

Associate Director
Los Angeles, United States
Oaklins Intrepid

Related deals

MEDIK Hospital Design Group has been acquired by STERIS
Construction & Engineering Services | Healthcare

MEDIK Hospital Design Group has been acquired by STERIS

The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.

Learn more
bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Healthcare

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Learn more
SLT has been acquired by Indutrade
Healthcare

SLT has been acquired by Indutrade

SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.

Learn more